Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients

Stanic, Karmen; Turnsek, Nina; Vrankar, Martina

doi:10.2478/raon-2019-0053

References

Brierly DJ, Gospodarowicz MK, Witekind C, editors. TNM classification of malignant tumours. 8th edition. Oxford: Wiley-Blackwell; 2017. p. 114-20.
Search in Google Scholar Back to article
Sobin LH, Gospodarowicz MK, Witekind C, editors. TNM classification of malignant tumours. 7th edition. Oxford: Wiley-Blackwell; 2009. p. 138-46.
Search in Google Scholar Back to article
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097/JTO.0b013e31812f3c1a
Open DOI Search in Google Scholar Back to article
Kligerman S, Digumarthy S. Staging of non small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol 2009; 193:1203-11. doi: 10.2214/ AJR.09.3193
Open DOI Search in Google Scholar Back to article
Kim SY, Kim JS, Park HS, Cho MJ, Kim JO, Kim JW, et al. Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci 2005; 20: 121-6. doi: 10.3346/ jkms.2005.20.1.121
Open DOI Search in Google Scholar Back to article
Rami-Porta R, Asamura H, Goldstraw P. Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. Transl Lung Cancer Res 2015; 4: 415-23. doi: 10.3978/j.issn.2218-6751.2015.07.11
Open DOI Search in Google Scholar Back to article
Huang A, Li R, Zhao J, Wang X, Jin B, Niu Y, et al. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. Thorac Cancer 2016; 7: 614-8. doi: 10.1111/1759-7714.12364
Open DOI Search in Google Scholar Back to article
Park HJ, Oh HJ, Kim KH, Kim TO, Park CK, Shin HJ, et al. Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response. Thorac Cancer 2016; 7: 639-47. doi: 10.1111/1759-7714.12378
Open DOI Search in Google Scholar Back to article
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. doi: 10.1056/NEJMoa1606774
Open DOI Search in Google Scholar Back to article
Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, et al. The IASLC Lung Cancer Staging Project Proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. Thorac Oncol 2015; 10: 1515-22. doi: 10.1097/ JTO.0000000000000673
Open DOI Search in Google Scholar Back to article
Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014; 48: 173-83. doi: 10.2478/raon-2014-0016
Open DOI Search in Google Scholar Back to article
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017; 389: 917-29. doi: 10.1016/S0140-6736(17)30123-X
Open DOI Search in Google Scholar Back to article
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget 2017; 8: 21903-17. doi: 10.18632/oncotarget.15746
Open DOI Search in Google Scholar Back to article
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-25. doi: 10.1056/NEJMoa1713137
Open DOI Search in Google Scholar Back to article
Lee CK, Man J, Lord S, Cooper W4, Links M, Gebski V, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 210-16. doi: 10.1001/jamaoncol.2017.4427
Open DOI Search in Google Scholar Back to article
Kaderbhaï C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers (Basel) 2019; 11: E201. doi: 10.3390/cancers11020201
Open DOI Search in Google Scholar Back to article
Kaplan EL, Paul Meier. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457-81.
Search in Google Scholar Back to article
Rami-Porta R, Goldstraw P. Strength and weakness of the new TNM classification for lung cancer. Eur Respir J 2010; 36: 237-9. doi: 10.1183/09031936.00016210
Open DOI Search in Google Scholar Back to article
Doroshow DB, Herbst RS. Treatment of advanced non-small cell lung cancer in 2018. JAMA Oncol 2018; 4: 569-70. doi: 10.1001/jamaoncol.2017.5190
Open DOI Search in Google Scholar Back to article
Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, et al. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: results from a population-based study. Eur J Cancer 2015; 51: 2534-44. doi: 10.1016/j. ejca.2015.08.008
Open DOI Search in Google Scholar Back to article
National Comprehensive CancerNetwork. Non-small cell lung cancer. National Comprehensive Cancer Network Guidelinese. v.5. 2018. [cited 2018 Jul 25]. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Search in Google Scholar Back to article
Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v1-27, 2016. doi: 10.1093/annonc/mdw326
Open DOI Search in Google Scholar Back to article
Folkert MR, Timmerman R. Review of treatment options for oligometastatic non-small cell lung cancer. Clin Adv Hematol Oncol 2015; 13:186-93. PMID: 26352427
Search in Google Scholar Back to article
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 2017; 3: 827-31. doi: 10.1001/ jamaoncol.2016.3834
Open DOI Search in Google Scholar Back to article
Miyaji N, Miki T, Itoh Y, Shimada J, Takeshita T, Churei H, et al. Radiotherapy for adrenal gland metastasis from lung cancer: report of three cases. Radiat Med 1999; 17: 71-5. PMID: 10378656
Search in Google Scholar Back to article
Pardo Aranda F, Larrañaga Blanc I, Rivero Déniz JR, Trujillo JC, Rada Palomino A, García-Olivares E, et al. Surgical treatment of lung cancer with synchronous adrenal metastases: adrenalectomy first. Cir Esp 2017; 95: 97101. doi: 10.1016/j.ciresp.2017.01.003
Open DOI Search in Google Scholar Back to article
Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, et al. Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. J Thorac Oncol 2019; 14: 1223-32. doi: 10.1016/j.jtho.2019.03.015
Open DOI Search in Google Scholar Back to article

Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients

References

Paradigm

My account